

1 **Machine learning approaches classify clinical malaria outcomes based on** 2 **haematological parameters**

3 Collins M. Morang¹, Lucas Amenga-Etego^{1,*}, Saikou Y. Bah^{1,2}, Vincent Appiah¹, Dominic S. Amuzu¹,
4 Nicholas Amoako¹, James Abugri³, Abraham R. Oduro⁴, Aubrey J. Cunnington⁵, Gordon A. Awandare¹,
5 and Thomas D. Otto^{6,*}

6 ¹West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), University of Ghana, Accra,
7 Ghana

8 ²Florey Institute, Molecular Biology and Biotechnology, University of Sheffield, Sheffield, UK

9 ³Department of Applied Chemistry and Biochemistry, C.K Tadam University of Technology and Applied
10 Sciences, Navrongo, Ghana

11 ⁴Navrongo Health Research Centre (NHRC), Navrongo, Ghana.

12 ⁵Section of Pediatric Infectious Disease, Department of Infectious Disease, Imperial College London, UK

13 ⁶Institute of Infection, Immunity & Inflammation, MVLS, University of Glasgow, Glasgow, UK

14 *Correspondence: lamenga-etego@ug.edu.gh & Thomasdan.otto@glasgow.ac.uk

15 **Keywords:** Machine Learning, Uncomplicated & Severe Malaria, and Classification

16 **Abstract**

17 **Background:** Malaria is still a major global health burden, with more than 3.2 billion people in 91 countries
18 remaining at risk of the disease. Accurately distinguishing malaria from other diseases, especially
19 uncomplicated malaria (UM) from non-malarial infections (nMI) remains a challenge. Furthermore, the
20 success of rapid diagnostic tests (RDT) is threatened by *Pfhrp2/3* deletions and decreased sensitivity at low
21 parasitemia. Analysis of haematological indices can be used to support identification of possible malaria

22 cases for further diagnosis, especially in travelers returning from endemic areas. As a new application for
23 precision medicine, we aimed to evaluate machine learning (ML) approaches that can accurately classify
24 nMI, UM and severe malaria (SM) using haematological parameters.

25 **Methods:** We obtained haematological data from 2,207 participants collected in Ghana; nMI (n=978), UM
26 (n=526), and SM (n=703). Six different machine learning approaches were tested, to select the best
27 approach. An artificial neural network (ANN) with three hidden layers was used for multi-classification of
28 UM, SM, and uMI. Binary classifiers were developed to further identify the parameters that can distinguish
29 UM or SM from nMI. Local interpretable model-agnostic explanations (LIME) were used to explain the
30 binary classifiers.

31 **Results:** The multi-classification model had greater than 85 % training and testing accuracy to distinguish
32 clinical malaria from nMI. To distinguish UM from nMI, our approach identified platelet counts, red blood
33 cell (RBC) counts, lymphocyte counts and percentages as the top classifiers of UM with 0.801 test accuracy
34 (AUC = 0.866 and F1-score = 0.747). To distinguish SM from nMI, the classifier had a test accuracy of
35 0.960 (AUC= 0.983, and F1-score = 0.944) with mean platelet volume and mean cell volume being the
36 unique classifiers of SM. Random forest was used to confirm the classifications and it showed that platelet
37 and RBC counts were the major classifiers of UM, regardless of possible confounders such as patient age
38 and sampling location.

39 **Conclusions:** The study provides proof of concept methods that classify UM and SM from nMI, showing
40 that ML approach is a feasible tool for clinical decision support. In the future, ML approaches could be
41 incorporated into clinical decision-support algorithms for the diagnosis of acute febrile illness, and
42 monitoring response to acute SM treatment particularly in endemic settings.

43 **Background**

44 In 2018, there were 228 million cases of malaria worldwide, 93% of which occurred in the African region
45 [1]. Furthermore, approximately 450,000 deaths were reported, of which 61 % were children under 5 years
46 old [1]. According to WHO 2018 report, over 2.7 billion US dollars were spent towards various control
47 and elimination efforts to address the global burden of malaria [1]. This includes over 2.74 billion doses of
48 artemisinin based combination therapies, procured in 2017 [1]. Unfortunately, incorrect diagnosis leads to
49 incorrect treatment. It can increase the chances of antimalarial drug resistance, or for false negative
50 diagnosis, it may result in misdiagnosis of malaria, appropriate treatment and progress to severe disease or
51 death [2–4]. The gold standard for malaria diagnosis is microscopy, which requires extensive training, but
52 rapid diagnostic tests (RDTs) have become the frontline diagnostic tools for malaria because of their ease
53 of use at point-of-care [5].

54 One drawback of RDTs is the emergence of gene deletions of the target antigen, histidine rich protein
55 (*Pfhrp2/3*), in the parasite genome, which render parasites undetectable by the most common RDTs [6].
56 Other challenges include insufficient sensitivity to detect low-level parasitemia, and the number of tests
57 which need to be performed per positive result in settings with declining or low transmission [7–9].
58 Different problems are faced in non-endemic countries, where imported malaria must be suspected as a
59 possible cause of fever before an RDT or microscopy would be performed in the first place, and failure to
60 identify cases at first contact with health services often results in worse clinical outcomes [10, 11].
61 Therefore, improved and complementary malaria diagnostics techniques are required, which can overcome
62 some or all of these limitations.

63 Complete blood counts (CBCs) is the most commonly performed laboratory test in most hospitals in both
64 developing and developed countries. The CBC is usually relied upon to provide clues for diagnosis of
65 patients where advanced methods for detection of specific diseases are lacking, with a parameter such as
66 decreased platelet counts often associated with severe malaria (SM) [12, 13]. In addition, hemoglobin levels
67 (Hb) are very important for the classification of SM cases [14]. Indeed, the changes in haematological

68 parameters during clinical malaria have been studied extensively, to aid in the understanding of disease
69 pathogenesis [15–21]. However, the diagnostic value of haematological parameters measured by commonly
70 available automated haematology analyzers has not been fully studied using unbiased approaches such as
71 ML techniques. These haematological parameters have the potential to be used in differentiating clinical
72 malaria from other febrile illnesses, especially in areas where the reliability of RDTs is challenged by high
73 prevalence of *Pfhrp2/3* deletion mutant parasites.

74 The potential and diagnostic value of all the CBC parameters for diagnosis of malaria can be realized by
75 using machine learning (ML). ML approaches use algorithms based on statistical assumptions and
76 mathematical rules to learn patterns and produce meaningful classifications based on the association of each
77 variable with the disease outcome [22–26]. These classifications can then be applied to new disease cases
78 to make classifications on the most probable cause. This classification capability of ML has not been
79 extensively implemented in the diagnosis of clinical malaria.

80 To date, only a single study has reported the use of ML to diagnose malaria using clinical history and
81 symptoms captured verbally and visually [27]. The sample size (n=376) was very small to deduce
82 meaningful classifications and the author concluded that more work would be needed [27]. Despite this,
83 there have been far reaching studies on application of ML in other areas of malaria research [28–32]. The
84 diagnosis of malaria using ML on clinical datasets has been impaired by lack of large data, as well as
85 difficulty in data curation. Moreover, classical modelling is prone to over-fitting or under-fitting of data
86 [33], but recent approaches such as imputation, encoding, centering and scaling of variables, and model
87 optimization [26] enable augmented use of ML in malaria classification.

88 We hypothesized that we can classify clinical malaria and non-malarial infections (nMI) with an ML
89 approach. We first collected and curated data from 2,207 patients including (nMI) (n=978), uncomplicated
90 malaria (UM) (n=703), and severe malaria (SM) (n=526). We generated ML models to classify clinical
91 malaria (UM and SM) from nMI using haematological parameters.

92 **Methods**

93 **Study population and sample collection**

94 Standards for Reporting Diagnostic Accuracy Studies (STARD) guidelines [34, 35] were followed in this
95 study. The current study utilizes unpublished data of 868 patients from a previous case-control study of SM
96 conducted by the Navrongo Health Research Centre (NHRC) located in the Kassena-Nankana Districts
97 (KNDs) in the Upper East Region of Northern Ghana. In the original study, children with acute febrile
98 symptoms admitted to the Navrongo War Memorial Hospital (NWMH), the only referral facility in the
99 KNDs were evaluated for inclusion into the study from August to December 2002 and May 2003 to April
100 2004. Full details of the study procedure, inclusion criteria, demographic and clinical characteristics of SM
101 cases may be reviewed in Oduro et al [36].

102 In brief, inclusion criteria for SM cases was: (1); all children between 6-59 months who had fever (or
103 history of fever in past 24 hours) and were admitted to the (NWMH), (2) residence in the Navrongo Health
104 and Demographic Surveillance System area [36], and (3) willingness of parents/caregivers to offer informed
105 consent. Criteria for SM diagnosis and enrollment into the original study were classified as having SM by
106 the WHO standard guidelines, that include hemoglobin < 5g/dl or hematocrit < 15% [36, 37]. Ethical
107 approval for the SM study was obtained from Navrongo Health Research Center (NHRC) Institutional
108 Review Board (IRB), Noguchi Memorial Institute of Medical Research (NMIMR) IRB, Naval Medical
109 Research Center IRB, and the Ghana Health Service (GHS) Ethics Committee. Informed consent was
110 obtained and documented, followed by administration of a questionnaire about the presenting symptoms
111 and clinical examinations. Participants who did not consent, meet the study inclusion criteria and those who
112 had reported taking antimalarial treatment in the past two weeks were excluded from the study, while those
113 who turned out to be malaria negative by standard microscopy were withdrawn from the study. All study
114 samples were taken prior to initiation of treatment except for samples taken for clinical monitoring during
115 admission or for the follow-up after discharge from hospital.

116 The nMI and UM participants were recruited in a hospital-based cross-sectional study involving two
117 hospitals; Kintampo North-Municipal Hospital, Kintampo and Ledzokuku Krowor Municipal Assembly
118 Hospital (LEKMA), Teshie in Accra. The inclusion criteria were; (1) outpatient children 1-15 years old,
119 (2) presenting with fever or history of fever in the past 24 hours or axillary temperature $\geq 38^{\circ}\text{C}$, (3) and (4)
120 signed informed consent by self (adolescents) and parent/guardian. The exclusion criterion was participants
121 with known chronic disease or history of antimalarial drug use in the past two weeks. Ethical approval was
122 also obtained from NMIMR, GHS, and Kintampo Health Research Centre (KHRC). A case was defined as
123 nMI if the individual presenting to the hospital was malaria negative by RDTs and microscopy. Clinical
124 data such as age, sex, body temperature and symptoms such as fever were collected on recruitment.

125 **Sample Collection Procedure**

126 Venous blood was collected in the ante-cubital fossa. Tourniquet was not applied beyond one
127 minute during venesection to avoid haemo-concentration, which could give erroneous results for
128 all parameters measured. Samples were taken mostly between 8 am and 12 pm to avoid variations
129 due to individuals' activity (such as rehydration and food intake). Samples (5 mL) were taken into
130 K3 EDTA tubes (BD Vacutainer; Becton Dickinson, NJ, USA). Samples that could not get
131 analyzed within two hours from the time of collection were stabilized at $2-8^{\circ}\text{C}$ to avoid changes
132 that could occur in some haematological parameters should the sample be left on the bench for
133 more than three hours. Samples were analysed not later than 24 hours from the time of sample
134 storage at $2-8^{\circ}\text{C}$. No capillary blood sample was taken during the study as it presents with subtle
135 variations from venous blood parameters. CBC analysis was performed using the automated ABX
136 Micros 60 haematology analyzer. Data were manually cross-referenced twice for accuracy to
137 ensure consistency in sample collection procedures.

138 **Statistical classifier: median split**

139 Kernel density estimation, which is a non-parametric technique, was used to estimate the probability density
140 function of each haematological parameter and kernel distribution for each parameter between nMI, UM
141 and SM and visualized using density plots in R (R-version 4.0.2). Median value within each diagnostic
142 group (nMI, UM, and SM) was computed, and the mean of any two group medians was used for ‘median
143 split’ to generate a dichotomous variable for each parameter (low and high levels representing below and
144 above median respectively)[38]. Contingency tables were used to summarize the relationship between
145 clinical diagnosis (nMI, UM, and SM), and each dichotomous parameter. The general linear models for
146 predictive analysis were used to explain the relationship between the clinical diagnosis and the dichotomous
147 parameter. Odds ratios were computed through the exponent of the regression coefficients (logits) to
148 estimate the strength of the relationship. Any OR with 95% confidence interval (CI) that includes a null
149 value (1.0) indicated that the parameter was not significantly associated with clinical diagnosis. ANOVA
150 was used to compare the model with null model and Chi-square test used to compute the degree of
151 significance. All the analysis was done in R (R-version 4.0.2)

152 **Data pre-processing and normalization**

153 A multivariate imputation via chained equations (MICE) plot was used to visualize the missing observations
154 in the data. It was difficult to determine whether the missing values were missing ‘completely at random’,
155 or ‘missing at random’ or ‘not at random’ to enable selection of imputation method. Therefore, the
156 demographic/clinical data and microscopy results were not imputed and were not used for modeling. The
157 majority of the haematological parameters had less than 5 % missing data and the missing values were
158 imputed using MICE package in R. Each variable in the training and test data were transformed using Yeo-
159 Johnson function, centered to have a mean of zero, and scaled to have a standard deviation of one. The
160 original dataset (before pre-processing and normalization) is available in Additional File 1.

161 **Machine learning**

162 Six ML algorithms were evaluated to identify the best algorithm that can classify the binary data. These
163 include partial least squares (PLS) logistic regression, multiple adaptive regression splines (MARS),
164 random forest, decision trees, support vector machine and artificial neural networks. PLS logistic regression
165 was implemented by reducing the dimension of haematological parameters so as to increase accuracy. We
166 used 10-fold cross-validation while tuning through 16 principal components (PC), whereby the optimal
167 model used 2 PC. The optimal hyperparameters for MARS (with cross validation) were determined in a
168 grid search of 30 different combinations of 3rd degree and sampling 1000 terms to retain the final model
169 [40]. Decision tree were implanted with the *rpart* function, which performs auto tuning with an optimal
170 subtree of 10 total tree splits. Random forest and support vector machines were implemented by first
171 performing a grid search to identify the optimal hyperparameters followed by classification analysis. Three
172 ANN were developed, one multi-classification ANN (nMI vs UM vs SM) and two binary classifications
173 denoted as ANN (UM and nMI), and ANN (SM and nMI). For each ANN, the data were split into 80 %
174 training and 20 % testing. The outcome was the clinical diagnosis of the participant (as concluded by the
175 attending clinicians) having either UM or nMI or SM. Haemoglobin and hematocrit levels were not
176 included in the modeling because they are used to support diagnosis of malaria [12, 21, 37, 39]

177 **Hyperparameter tuning for artificial neural networks**

178 The ANN was composed of an input layer of 15 haematological parameters. The loss was computed using
179 categorical cross-entropy for the multi-classifier and binary cross-entropy for binary classifiers, while
180 accuracy was used as the main evaluation metric. During training, the 80 % training data was further split
181 into 70 % training and 30 % validation with randomization (Figure 1). Tensor board visualizations were
182 used to check the dynamic graphs of our training and test metrics (Supplementary figure 2).
183 Hyperparameters were tuned to identify the optimal model parameters for each classification. A hyper-grid
184 was developed that adjusts the model capacity, normalization term, kernel regularization, and learning rate.
185 To maximize the validation error performance, we tuned 12, 32, 64, 128, 256, 512 rectified linear units

186 (ReLU) in three hidden layers. We used batch normalization on each hidden layer for gradient propagation
187 and performance improvement. We varied the dropout rate from 0.1, 0.2, 0.3, and 0.4 in all the three layers
188 to identify the best dropout regularization that prevents the model from latching to happenstance patterns
189 that are not significant. We used “Adam” as the optimizer, but we varied the learning rate (0.1, 0.05, 0.001,
190 and 0.0001) to find a global minimum. The tfruns R package was used to implement the hyper-grid in R,
191 using 500 epochs, batch size of 64 and validation split of 0.3. These Keras models composed were initialized
192 for all the three models (supplementary figure 1) and the optimal model was selected.

193 **ANN Model evaluations**

194 Yardstick package was used to perform classifications on the test data as well as compute the performance
195 of the model. The confusion matrix, accuracy, area under the Receiver Operating Characteristic Curve
196 (AUC), precision and recall, and F1- Score were the metrics used to evaluate performance. The F1 score is
197 a measure of test data accuracy, which is a weighted average between precision and recall. To explain the
198 model, we used local interpretable model-agonistic explanations (LIME Package in R) [41]. The
199 classification model was set up, and an “explainer” of the classifying model was developed using the
200 training data and the model output classifications. The explainer was used to explain the results of the test
201 dataset as classification explanations (feature weights). The feature weights were used to build a heatmap
202 for each ANN indicating how each feature explains the model.

203 **Effect of patient age and sampling location on the model predictions**

204 To test if patient age and sampling location significantly affected the models, we used three models
205 (1) a model for all the UM and nMI cases (n=1,823), (2) a model for UM and nMI from Kintampo
206 cases only (n=900), and (3) a model for only Kintampo cases and ages >4 years. We tested the
207 possibility of using the ANN to evaluate the models but there was some level of over-fitting and
208 under-fitting of the 2nd and 3rd models, due to sample size limitation. Therefore, random forest was

209 subsequently used, because of (1) its robustness to smaller sample size with minimal over-fitting
210 of the data (2) its ability to reduce the high variance from decision trees by combining several
211 trees into one ensemble tree [42].

212 **Statistical analysis**

213 The clinical categorical data was analyzed using Pearson's Chi-square while the continuous data such as
214 the haematological parameters were analyzed using Kruskal Wallis test with Dunn's post hoc tests across
215 the three groups (UM, SM and nMI). All tests were two sided and statistical significance was set at ($P < 0.05$)
216 for all analyses with adjustment for multiple testing. Data analyses was performed using R-development
217 software (R version 4.0.2), R-studio (Version 1.1) and Python (Version 2.7). The R code with the methods,
218 including the curated data files can be found on git-hub: <https://github.com/misita-falcon>.

219 **Results**

220 **Characteristics of the study participants**

221 Participants were recruited as follows; 38.8 % (857/2,207) from Accra, 32.9 % (726/2,207) from Kintampo,
222 and 28.3 % (624/2,207) from Navrongo (Figure 1). These participants from all the three locations constitute
223 44.3 % (978/2,207) nMI, 31.8 % (703/2,207) for UM, and 23.8 % (526/2,207) for SM cases (Figure 1). The
224 median age was 3 years (range: 2-6 years) for nMI, 4 years (range: 2-7 years) for UM, and 1 year (range:
225 1-2 years) for SM. The median ages were significantly different as determined by Kruskal Wallis test
226 ($P < .001$) (Table 1). The sm cases had a significantly higher median body temperature (38.3; range =37.5-
227 39.2), compared to the nMI (37.2; range = 36.5-38.4), UM (38.1; range = 37-39) and the SM cases (38.3;
228 range =37.5-39.2) ($P < .001$). There was a significant difference in proportions of individuals ($P < .001$)
229 among nMI, UM, and SM from different locations (Kintampo, Navrongo, and Accra) as determined by chi-
230 square analysis (Table 1). There was no association between sex and clinical diagnosis, although the number
231 of females was higher than males in all three groups ($P = 0.247$); nMI was 51.2 % (501/978), UM was 54.9

232 % (386/703) and SM was 55.1 % (290/526) (Table 1). Fever was more common in SM (99.2 %, 522/526)
233 compared to UM (85.5 %, 601/703) and lowest in nMI (59.4%, 581/978), and chi-square analysis shows
234 that there was an association between fever and clinical diagnosis ($P<.001$) (Table 1).

235 Participants with UM had a higher geometric mean density (27,467.59 Parasites/ μ L, SD=8.44) compared
236 to SM individuals (16,674.41 Parasites/ μ L, SD=8.61). But, the median levels did not vary significantly
237 between the two groups ($P=0.592$) (Table 1). Participants with nMI were negative by microscopy. There
238 were 212 different suspected infections in the nMI group and the top 10 include; upper respiratory tract
239 infections (17 %, 167/978), malaria (9.5 %, 93/978), gastroenteritis (7.6 %, 75/978), sepsis (6.1 %, 60/978),
240 otitis media (5.9 %, 58/978), enteric fever (2.6%, 26/978), fever (2.1 %, 23/978), tonsillitis (2.3 %, 23/978),
241 pneumonia (2.1%, 21/ 978) and anaemia (1.9 %, 19/978) (supplementary figure 1). Laboratory results
242 indicated that majority of the samples were undetermined/not available/not known (96 %, 937/978), with
243 only 4 % having accurate laboratory result (41/978). Some of the organisms that were laboratory confirmed
244 include; *Streptococcus pneumoniae*, *Staphylococcus aureus*, *Salmonella typhi*, *Coxiella burnetii*, and
245 Dengue virus (Figure 2). Only 2 UM participants had co-infections (laboratory confirmed) with *P.*
246 *falciparum* and these individuals had 4 and *Group D streptococcus* (1). Since the sample size of laboratory
247 confirmed nMI cases was low, all the samples were grouped as nMI, instead of individual diseases during
248 ML classifications.

249 **Haematological parameters vary between nMI, UM and SM**

250 Median values for all the haematological parameters were significantly different among nMI, UM, and SM
251 ($P<.001$) (Table 2), but most of the parameters do not show distinct distributions between the different
252 clinical diagnosis groups (Figure 3). More so, Dunn's post hoc tests indicated that platelet distribution
253 width, percentage neutrophils and percentage lymphocytes were not significantly different between the nMI
254 and SM (Table 2). Similarly, the pairwise comparisons showed that mean cell volume Neutrophils count
255 and mean platelet volume were not significantly different between nMI and UM (Table 2). Despite the

256 statistical test, we hypothesized that the median differences for each parameter cannot be used to confidently
257 classify the disease outcomes.

258 To further confirm this hypothesis, the median was used to split the variables into categorical variables (low
259 and high levels). The relationship or predictive value of the categorical parameters to accurately classify
260 the clinical diagnosis was determined using contingency tables (Additional File 1, sheet 2). The percentage
261 number of individuals who had low levels of each parameter and were classified with nMI ranged from 29
262 -70 % (UM group), 7-82 % (SM-group) (Figure 4A). Comparatively, the percentage of individuals who
263 had low levels of each parameter and were classified with UM ranged between 30 - 71 %, while the
264 percentage of individuals who were classified with SM ranged between 17 – 91 % (Figure 4B). There were
265 similar trends for percentage number of individuals who had high levels of each parameter and were
266 classified with either nMI, UM, and SM (Figure 4C –D).

267 Additionally, we determined whether the levels could predict whether an individual has UM or SM. First,
268 we predicted UM, and majority of the parameters were associated with clinical diagnosis of SM and nMI
269 ($P < .001$), except mean cell volume, mixed cells counts and neutrophil counts. The parameters that were not
270 associated for nMI-UM category were WBC and RBC counts, Mixed cells percentage, neutrophil
271 percentages, mean cell Hb concentration, mean platelet volume and neutrophil counts (Supplementary
272 Table 2). Furthermore, some of the haematological parameters had a 95 % confidence interval that included
273 the null value (1) when evaluating the odds ratios, which signifies that they are not significantly associated
274 with clinical diagnosis (Supplementary Table 2).

275 **Machine learning attained over 77.7 % accuracy in classifying clinical malaria from nMI**

276 Since there is no clear distinction between the distributions, and the inability of the median based categories
277 to clearly classify the participant's clinical diagnosis, we sought to evaluate six ML approaches to classify
278 clinical malaria from nMI. The UM vs nMI model was trained on 942 samples, validated on 403 samples,
279 and tested on 336 samples for each ML approach. The SM vs nMI model was trained on 843 samples,

280 validated on 361 samples, and tested on 300 samples for each ML approach (Figure 1). Amongst the six
281 ML approaches, the training accuracies ranged between 0.794 – 0.857 to classify UM while the training
282 accuracies ranged between 0.937- 0.985 in classifying SM. The test accuracies ranged from 0.777 to 0.857
283 for the UM model, and 0.930 to 0.973 for SM model (Supplementary Table 3). The SVM approach and the
284 ANN generated the overall best classification outcome.

285 Hyperparameter tuning (n=55,290 combinations) showed that the optimal model for multi-classification
286 had 0.831 training accuracy with a model capacity of 3 layers (128, 64 and 16), with dropouts of 0.4 for
287 layer 1, 0.3 for layer 2, and 0.4 for layer 3, and learning rate of 0.001. The optimal model (n=55,290
288 combinations) for ANN (nMI vs SM) with 0.975 accuracy had a model capacity of 3 layers (16, 128, and
289 256 RELU units respectively), the dropout rate was 0.2 and 0.4 for the first two layers, the last layer had
290 0.1, and a learning rate of 0.0001. The optimal model (n=55,290 combinations) for ANN (nMI vs UM) with
291 0.869 training accuracy had a model capacity of 3 hidden layers of 256, 64, and 16 RELU units respectively,
292 the dropout rate was 0.1 for the first and last layer and 0.3 for the second layer, and a learning rate of 0.0001.
293 Training and validation history plots for the ANN showed good levelling off for accuracy and loss, as well
294 as acceptable divergence between training loss/accuracy and validation loss/accuracy for all the three
295 models (Supplementary figure 3).

296 Also, the history plots suggest that there was near zero over-fitting or under-fitting of the data as indicated
297 by closeness of the training and validation curves (Supplementary figure 3). The ANN (UM vs. nMI),
298 achieved 0.856 training accuracy and 0.842 validation accuracy, while the testing accuracy of the model
299 was 0.801 (Kappa 0.583) (Table 3). The training and testing accuracies demonstrate the confidence of the
300 networks in classifying UM. The ANN (SM vs. nMI) achieved a higher accuracy (≥ 0.960) for training,
301 validation and testing accuracy (Table 3). Both ANN had an F1 score of above 0.747, which means the
302 model can be used for the classification of clinical malaria (Table 3). Since the binary classifiers had the
303 best performance, we also performed a multi-classification analysis to assess the ability of the ANN to

304 differentiate among UM, SM and nMI. The data available for the multi-classification model was 2,207
305 samples, which were split to 80 % training (n=1,766) and 20 % testing (n=441). The training data was
306 further split to 70 % (n=1,236) training and 30 % (n=530) cross-validation with accuracies of 0.862 and
307 0.828 respectively. The test accuracy was 0.853 ($\kappa = 0.768$), the precision, recall and F1-score of the
308 model was 0.747 (Table 3). The accuracy of multi-classification model provides confidence in the binary
309 classifications.

310 **Diagnostic value of the models using ROC curves**

311 Having shown the accuracy of the models, we determined the ROC curves of ANN (UM vs nMI) and ANN
312 (SM vs nMI) to show the diagnostic ability of these binary classifiers. Both classifiers had very good
313 performance with an AUC 0.866 for ANN (UM vs. nMI) and AUC of 0.983 for ANN (SM vs. nMI) (Figure
314 5 and Table 3). This showed that the models could be used to distinguish individuals with SM or UM from
315 those with nMI. The cut-offs for UM show that there is a trade-off in sensitivity and specificity as the cut-
316 off increases or decreases, which is not the case for SM. These results could frame the clinical utility of the
317 models and provide a benchmark for future studies.

318 **Platelet and RBC counts classify clinical malaria from non-malaria infections**

319 The models were investigated to identify which haematological parameters were classified to be important
320 for either SM, UM or nMI using local interpretable model-agnostic explanations (LIME). Case by case
321 analysis of the individuals showed that some haematological parameters are important classifiers of UM
322 (Supplementary figure 3). Case by case analysis was merged into heatmap to generate a consolidated picture
323 of useful parameters for classification (Figure 6). The top three parameters that had low feature weights for
324 UM are platelet counts, RBC counts and lymphocyte percentages (Figure 6A). Based on the order of
325 importance, the top three parameters that were important for SM classification include RBC counts, platelet
326 counts and mean platelet volume (Figure 6B). This shows that both platelet and RBC counts are important
327 parameters for clinical malaria while the lymphocyte percentages was unique for UM. These parameters

328 might be used to classify clinical malaria cases from nMI, with a very good diagnostic ability as shown by
329 the ROC analysis (Figure 4).

330 **Patient age and sampling location do not affect the model classifications**

331 We further tested if the models are agnostic to age and location variance. There was a significant difference
332 in patient age between nMI and UM ($P < .001$), but there was no significant difference in samples within
333 Kintampo as well as children under the age of 4 years (Figure 7, supplementary figure 5 & 6). The
334 performance accuracy of the random forest models was 0.806, 0.767, and 0.768 for model 1, 2 and 3
335 respectively (Figure 7). The most important parameters that featured across the three models were platelet
336 and RBC counts, which are similar to the top two parameters identified by the ANN. Therefore, the data
337 illustrates that age and location do not affect model classifications, and the platelet or RBC counts
338 determined by ANN can be used to reliably classify clinical malaria from nMI in these datasets.

339 **Discussion**

340 Automated CBC is one of the blood tests routinely performed for children presenting to health
341 facilities with fever. However, CBC analysis generates a significant amount of data on a range of
342 haematological parameters, the data is underutilized with only Hb and Hct levels being routinely
343 used as an indicator of clinical malaria. Thus, an automated algorithm to detect malaria based on
344 the haematological parameters as outlined in this study, could have great value as a complementary
345 malaria diagnostic strategy, particularly at front-line health centers where CBC is routinely done.
346 Such an algorithm also has the added value of enabling the monitoring of treatment outcomes for
347 in-patients.

348 In malaria endemic settings, malaria rapid diagnostic tests (mRDTs) have revolutionized diagnosis
349 and significantly reduced presumptive treatment, particularly in rural settings where trained

350 microscopists are lacking [3]. However, reports of emerging *Pfhrp2/3* gene deletions threaten the
351 future reliability of the RDTs. False negative RDT results are also known to occur in low density
352 infections [7–9]. Thus, an approach that is automated and agnostic to parasite genetic variation is
353 critical both as a fail-safe and a surveillance strategy for false negative mRDTs (which might occur
354 due to supply chain mismanagement or gene variation) [9]. In very low transmission settings, ML
355 models have the potential to replace the primary use of mRDTs when diagnostic yield of mRDTs
356 becomes very low (i.e. many mRDTs needed to detect a single case of malaria). In non-endemic
357 settings where malaria may occur in immigrants and non-immune travelers, the models may allow
358 another fail-safe mechanism in case the diagnosis of malaria was not suspected by clinicians and
359 malaria RDT or microscopy was not performed. Despite these advantages, there would be a little
360 extra cost associated with incorporating the algorithm and an automated message into haematology
361 analyzer output, a message that can prompt clinicians to consider malaria in the presence of
362 suggestive haematological features.

363 Previous ML studies have looked into haematological parameters more generally and to classify
364 sickle cell anaemia using deep convolutional networks [43, 44], but did not classify clinical
365 diagnosis. For the first time, ML approaches that can classify infections in children based on
366 haematological parameters have been generated. Six different ML methods were evaluated and
367 they were all shown to classify clinical malaria from nMI with high accuracy especially the SVM
368 and the ANN. We used the ANN to deconvolute the results: it identified platelet and RBC counts
369 as the top features in classifying both UM or SM from nMI. Low RBC counts can be attributed to
370 extensively parasitized RBCs, which are sequestered during SM [45]. This highlights the
371 significance of RBC counts during *Plasmodium falciparum* malaria infections. In most occasions
372 except cerebral malaria, SM is associated with anemia due to RBC lysis during parasite invasion

373 as well as many other RBC abnormalities [46]. This makes the diagnosis of SM much easier than
374 UM, whereby one parameter, such as Hb level of <5g/dL, can diagnose or classify the disease.

375 Cohen et al, analyzed data from 680,964 individuals with fever and confirmed that majority of
376 antimalarial drugs are given to malaria negative individuals [47]. Overtreatment indicates that,
377 most nMI can go without being treated, for their true cause, which is also possible for UM and this
378 can lead to drug resistance. Therefore, the difference between febrile outpatient infections is far
379 more challenging, especially between nMI and UM due to similarity in clinical presentations. In
380 large population studies, differences in median can be significant but they do not necessarily
381 distinguish the populations as either nMI or UM as observed in this study. But, using the ML
382 approach shown here, distinguishing the nMI and UM can be improved by combining all
383 haematological parameters and learning the data-patterns before making classifications. The
384 predictions made by ML are more accurate and reliable, and can be improved by analyzing more
385 datasets. Lymphocytes counts/percentage were identified to be affected during UM, and can be
386 used to distinguish UM from nMI, mainly because individuals with malaria generally have a
387 distinct immune response compared to nMI individuals [29, 48, 49].

388 Previous work in our laboratory showed differences in haematological presentation among areas
389 of varying transmission intensity in Ghana [50]. To show that differences in age and transmission
390 zones (sampling location) are not driving our diagnostic classifications, we down-sampled the data
391 and used random forest to perform the classifications. The results showed that, platelet and RBC
392 counts were the key features in classifying UM and nMI regardless of age and sampling location
393 of the participants. There were differences in the top three important features between the random
394 forest and ANN, but this could be due to the differences in approach of each algorithm [25, 51].

395 This illustrates that the patient age and location do not substantially influence the diagnostic
396 classifications. The ROC curves further showed that the models could be used for diagnosis with
397 very reliable AUC values.

398 There are four limitations to be considered in the use of this ML approach in routine diagnosis and the
399 generalization of our approach. First, the models can distinguish between nMI and clinical malaria, but
400 whether they can be used to distinguish the clinical disease state will depend on the pre-test probability or
401 prevalence of malaria in different settings. Second, all study subjects being Ghanaian children may limit
402 the generalizability of the models; this is also the case for the limited range of SM manifestations in our
403 dataset, and the spectrum of laboratory confirmed nMI. Lastly, the study did not have adults >15 years to
404 comparatively understand the role of age in differentiating clinical malaria based on haematological
405 parameters. Therefore, we recommend that more studies are needed to inform the broader utility of this
406 work. Despite that only 4.6 % (75/1,645) of the cases were discordant between microscopy and RDT,
407 probably due to *hrp2/hrp3* deletions, there is an insignificant chance that misclassification of malaria could
408 have had an impact on our study. These limitations will be taken into account for further studies to inform
409 the broader clinical utility of this work.

410 **Conclusions**

411 Fever is the most common symptom reported in sSA, and correct diagnosis of the implicated
412 pathogen is of high importance for precision medicine. Personalized treatment reduces
413 overtreatment, decreases malaria mortality and antimalarial resistance. This report demonstrates
414 proof-of-principle that ML can be used to distinguish clinical malaria from nMI using routine
415 haematological data. Case by case analysis showed that, the models can make classifications based
416 on combination of three parameters: platelet and RBC counts, lymphocytes counts/percentage and
417 mean platelet volume. These could be used for precision diagnosis of an individual's risk of having

418 malaria, to inform the need for confirmatory diagnosis by microscopy or to prompt investigation
419 for other diagnoses when malaria is unlikely. Further work is to calibrate and improve the
420 classification capability of the model using more data from other geographical and transmission
421 settings, demographic groups, co-infections, and different disease severities. Our findings hold
422 promise for the design of clinical software to support diagnosis of malaria in the WHO African
423 region, and might also prove useful for diagnosis of malaria in returning travelers from non-
424 endemic countries.

425 **Acknowledgments**

426 We acknowledge the study participants as well as the staff of Kintampo Municipal, who provided support
427 for this study. We are grateful to Emmanuel Allotey, Prince Nyarko, Henrietta Mensa-Brown, Felix Ansah,
428 Jersley Chirawurah, Jonas Kengne, and Nancy Nyakoe for their contributions on the data collection and
429 constructive criticism of the work. We also express our sincere gratitude to Dorothy Annan, Deborah
430 Mettle, Bright Yemi, Rachel Abban, Samirah Saiid, Joyceline Kwarko, and Israel Osei for assisting in
431 cross-referencing the data. We acknowledge University of Ghana for providing the high performance
432 computing resources (the ZUPUTO) used for this work.

433 **Author's Contributions**

434 CM, GA, LA, TO, SB, DA, AC, and VA contributed to design and conceptualization of the work, as well
435 as editing and critique of the manuscript drafts. LA, JA, DA, AO, and NA contributed to data collection.
436 CM performed data analysis, including building the models, model interpretation and drafting the
437 manuscript. All authors read and approved the final manuscript.

438 **Funding**

439 The study was supported by a DELTAS Africa grant (DEL-15-007: Awandare). The DELTAS Africa
440 Initiative is an independent funding scheme of the African Academy of Sciences (AAS)'s Alliance for

441 Accelerating Excellence in Science in Africa (AESAs) and supported by the New Partnership for Africa's
442 Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust
443 (107755/Z/15/Z: Awandare) and the UK government. The funder had no role in study design and where to
444 publish. The views expressed in this publication are those of the author(s) and not necessarily those of AAS,
445 NEPAD Agency, Wellcome Trust or the UK government.

446 **Availability of the data**

447 The dataset supporting the conclusions of this article is included within the article and its additional files.

448 **Ethics approval and consent to participate**

449 Ethical clearance was obtained from Ghana Health Service Ethics Review Committee and Noguchi
450 Memorial Institute of Medical Research Institutional Review Board. All participants were provided with
451 written informed consent prior to inclusion in the study.

452 **Consent for Publication**

453 All authors gave consent for publication

454 **Competing Interests**

455 The authors declare that they have no competing interests.

456

457 **Tables**

458 **Table 1 Characteristics of study participants for nMI, UM, an SM (n= 2,207).** Average age and
 459 hemoglobin levels were analyzed using Kruskal Wallis test while recruitment location, sex and fever were
 460 analyzed using Chi-square test at 95% CI. All the participant characteristics were significantly different
 461 between the nMI, UM, and SM.

Characteristic	Non-Malaria Infections		Uncomplicated Malaria		Severe Malaria		<i>p-value</i>
	N=2207	N=978 (44.3%)	N=703 (31.8%)	N=526 (23.8%)			
Patient Age							
Mean (SD)	4.23	(3.57)	4.95	(3.57)	1.66	(0.93)	< .001 ^a
Median (Range)	3.0	(2-6)	4.0	(2-7)	1.0	(1-2)	
Body Temperature							
Mean (SD)	37.4	(1.18)	38.1	(1.23)	38.4	(1.15)	< .001 ^a
Median (Range)	37.2	(36.5-38.4)	38.1	(37-39)	38.3	(37.5-39.2)	
Parasite Density							
Geometric Mean (SD)	0	0	27467.59	8.44	16674.41	8.61	0.592 ^c
Median (Range)	0	0	29,426	3,144-105,351	25,160	3,560-86,560	
Location							
Accra (n, %)	657	(67.2%)	200	(28.4%)	0	(0.0%)	<.001 ^b
Kintampo (n, %)	321	(32.8%)	405	(57.6%)	0	(0.0%)	
Navrongo (n, %)	0.0	(0.0%)	98	(13.9%)	526	(100.0%)	
Sex							
Female (n, %)	477	(48.8%)	317	(45.1%)	236	(44.9%)	0.209 ^b
Male (n, %)	501	(51.2%)	386	(54.9%)	290	(55.1%)	
Fever symptom							
No (n, %)	395	(40.4%)	97	(13.8%)	4	(0.8%)	<.001 ^b
Yes (n, %)	581	(59.4%)	601	(85.5%)	522	(99.2%)	
Missing (n, %)	2	(0.2%)	5	(0.7%)	0	(0%)	

462 ^a Kruskal-Wallis Test ^b Chi-square test ^c Dunn (1964) Kruskal-Wallis multiple comparison – UM vs SM only

463 **Table 2 Comparison of median and interquartile ranges in haematology values measured in nMI, UM, and SM cases.** *P-values* were analyzed
 464 using Kruskal Wallis test with post hoc tests (supplementary table 2). The parameters include WBC indices, RBC indices, and platelet indices. All the
 465 haematological parameters were significantly different between the nMI, UM, and SM ($P < 0.001$) except the WBC counts, neutrophil counts, percent
 466 neutrophils and mean corpuscular hemoglobin.

Parameters	Non-Malaria Infections (a) N=978		Uncomplicated Malaria (b) N=703		<i>a vs b</i> <i>P-value</i>	Severe Malaria (c) N=526		<i>b vs c</i> <i>P-value</i>	<i>a vs c</i> <i>P-value</i>	<i>a vs b vs c</i> <i>P-value</i>
	Media n	IQR	Median	IQR		Median	IQR			
WBC Indices										
WBC Count ($10^3/\mu\text{L}$)	9.3	7.0-12.8	8.3	6.3-10.8	< .001	11.6	8.3-16.6	< .001	< .001	<.001
Lymphocytes Count ($10^3/\mu\text{L}$)	3.0	2.0-4.5	1.9	1.3-3.0	< .001	3.8	2.4-6.0	< .001	< .001	<.001
Mixed Cell Count ($10^3/\mu\text{L}$)	0.8	0.5-1.1	0.5	0.3-0.8	< .001	0.9	0.5-1.4	< .001	0.004	<.001
Neutrophils Count ($10^3/\mu\text{L}$)	4.8	3.3-7.6	5.4	3.7-7.6	0.115	6.5	4.4-9.4	< .001	< .001	<.001
Lymphocytes Percent (%)	35.8	22.6-47.8	24.7	16.8-36.8	< .001	33.9	26.5-44.4	< .001	0.964	<.001
Mixed Cells Percent (%)	8.6	6.7-11.0	6.9	5.0-9.2	< .001	8.2	5.5-11.3	< .001	0.012	<.001
Neutrophils Percent (%)	54.4	41.7-69.0	67.8	53.7-77.1	< .001	55.8	46.6-66.2	< .001	0.568	<.001
RBC Indices										
RBC Count ($10^6/\mu\text{L}$)	4.5	4.2-5.0	4.1	3.6-4.5	< .001	2.4	1.7-3.2	< .001	< .001	<.001
Hb Level (g/dL)	11.0	10.1-11.8	10.1	8.8-11.2	< .001	5.6	4.1-7.4	< .001	< .001	<.001
Hematocrit (%)	34.5	32-37.1	31.1	27.2-34.8	< .001	16.7	12.0-21.1	< .001	< .001	<.001
RBC Distribution Width (%)	15.1	14.0-16.6	15.7	14.7-17.1	< .001	18.1	16.2-20.1	< .001	< .001	<.001
Mean Cell Volume (fL)	76.0	71.2-80.3	76.0	72.0-81.0	0.510	70.0	64.7-75.4	< .001	< .001	<.001
Mean Corpuscular Hb (pg)	23.7	21.8-25.6	24.9	23.0-26.4	< .001	23.8	21.5-26.7	0.001	0.006	<.001
Mean Cell Hb Concentration (g/dL)	31.6	29.6-32.5	32.3	31.5-33.3	< .001	35.1	31.2-37.4	< .001	< .001	<.001
Platelet Indices										
Platelet Count ($10^3/\mu\text{L}$)	292.0	226.0-360.0	140.0	92.0-216.0	< .001	98.0	61.0-156.0	< .001	< .001	<.001
Mean Platelet Volume (fL)	8.2	7.6-8.9	8.1	7.5-8.9	0.186	6.9	6.4-7.8	< .001	< .001	<.001
Platelet Distribution Width (fL)	15.0	13.9-15.4	14.5	12.4-15.6	0.005	15	12.0-17.3	< .001	0.121	<.001


467 *P-value* – Kruskal Wallis test with Dunn's post hoc tests

468 **Table 3 Performance of classification models for identifying parameters that can be classified with**
 469 **clinical malaria.** Training and cross-validation accuracy as well as testing accuracy, area under the ROC
 470 curve (AUC), Precision, Recall and F1-score. Multiclass analysis among all three-disease conditions,
 471 training accuracy was 0.862 with 0.828 validation accuracy. The model classified the three classes with
 472 0.853 test accuracy. The ANN (UM vs nMI) had accuracy of ≥ 0.801 for training, validation and testing
 473 accuracy. The ANN (SM vs nMI) had the highest classification accuracy of ≥ 0.960 .

ANN	UM vs SM vs nMI	UM vs nMI	SM vs nMI
Model type	Multi-classification model	Binary model	Binary model
Data splitting			
Total data (100%)	n=2207	n=1681	n=1504
Training & validation data (80%)	n=1766	n=1345	n=1204
Testing data (20%)	n=441	n=336	n=300
Training performance			
Training accuracy	0.862	0.856	0.985
Training Loss	0.396	0.425	0.062
Validation accuracy	0.828	0.842	0.978
Validation loss	0.432	0.434	0.102
Testing performance			
Testing accuracy	0.853	0.801	0.960
Kappa	0.768	0.583	0.913
ROC_AUC	NA ^a	0.866	0.983
Precision	0.855	0.780	0.971
Recall	0.856	0.717	0.918
F1- Score	0.856	0.747	0.944

474 ^a We did not generate ROC-AUC for multiclassification models


475



476


477 **Figure 1. Study population and data splitting for building the ANN for clinical malaria.** Samples were
 478 collected from two high transmission areas; Kintampo (n=726) and Navrongo (n=624), and one low
 479 transmission area (Accra, n = 857). The nMI (n = 978) were collected from Kintampo and Accra, UM (n =
 480 703) were collected from all three areas, while the SM (n= 526) samples were collected from Navrongo. A
 481 multi-classification ANN model was developed for nMI, UM and SM, which was further evaluated by
 482 binary ANN models (1) ANN (UM vs nMI) and (2) ANN (SM vs nMI). For each model, data splitting was
 483 achieved by splitting data in 80:20% ratio into training (Train) and testing (Test). The 80% training data
 484 was further split into 70:30% ratio for training (Train) and cross-validation (xVal-set).

485




487 **Figure 2. Clinical manifestations using laboratory diagnosis compared to various suspected infections**
488 **by clinicians.** Blood, urine and stool samples were collected from majority of the individuals who were
489 categorized as nMI. Cultures of either blood, urine or stool were performed, depending on the
490 clinicians/Doctor's request and the suspected illness. The suspected organisms include bacteria, viruses and
491 protozoan. Laboratory results confirmed only 4% of the cases with the majority being undetermined/not
492 available/not known (96 %, 937/978). The major organisms determined to be present include: Dengue virus,
493 *Staphylococcus aureus*, *Salmonella typhi*, *Streptococcus pneumonia*, and *Coxiella burnetii*.

494



497 **Figure 3: Density estimates of the haematological parameters between nMI, UM and SM cases.** A
498 kernel density-plots indicates the distribution of haematological data across each parameter. The plot uses
499 kernel density estimate to plot allowing for smoother distributions by smoothing out the noise. The peaks
500 of each density plot are displaying the help display where values are concentrated over the interval. Each
501 plot is labelled under it the parameter it's estimating.

502



503

504 **Figure 4 Non-symmetrical predictive values of clinical diagnosis using median cut-off (high vs Low)**

505 **of the haematological parameters.** A “median split” was used to divide each quantitative parameter into

506 categorical variables by the median value (calculated as a mean of nMI and UM or SM median value shown

507 in Table 2). The predictive values are calculated from contingency tables (Supplementary Table 2). (A)


508 Shows the percentages of predicting nMI from low levels, (B) percentages of predicting SM or UM using

509 the low levels, (C) percentages of predicting nMI using high levels and (D) predictive values of UM or SM

510 using high levels.

511

512




513

514 **Figure 5 ROC curve for classification of SM was near perfect.** The ROC curves plots sensitivity versus
515 specificity for all possible cut offs. Each point on the curve represents a different cut-off value, which are
516 connected to form a curve. The diagonal line is a reference line for the ROC curve. A) ROC for the ANN
517 (UM vs nMI) with an area under the curve (AUC) of 0.866 which is basically an average of true positive
518 rate across all possible false positive rates. B) ROC for the ANN (SM vs nMI) is right angled which means
519 its near perfect with an AUC of 0.983. The levels of AUC indicate a good performance of the models in
520 classifying UM and SM.

521

522

523



524

525 **Figure 6 Platelet and RBC counts classified as classifiers of both UM and SM.** The Keras model was

526 explained using local interpretable model-agonistic explanations (LIME Package in R-software). The

527 explainer results of the test data, which are represented as feature weights, were extracted from the


528 explainer and used to plot the heatmaps to show a consolidated effect of the parameters. The weights that

529 are < -0.1 indicate that they are low during UM or SM. **Left** heatmap shows that platelet, RBC, and

530 lymphocytes percentages/counts, can classify UM. **Right** heatmap shows the haematological parameters

531 that can classify SM, and they include RBC counts, mean platelet volume, platelet counts and MCV.

532



533

534 **Figure 7 Classification of haematological parameters using random forest shows that patient age and**

535 **sampling location do not affect the ML models.** Three models were generated; (A) a model for all the

536 UM and nMI cases (n=1,681), (B) a model for UM and nMI from Kintampo cases only (n=735), and (C) a

537 model for only Kintampo cases and ages >4 years, whereby there was no significant difference between the

538 nMI and UM (n=414). The samples for each model were split 80% training and 20% for testing. The

539 accuracy of the models was 0.806, 0.767 and 0.768 respectively. The most important parameter across the

540 three models was Platelet and RBC counts.

541

542 **Supplementary Tables**

543 **Supplementary Table 1 The list of haematological parameters adopted from laboratory procedure**

544 **manual by the CDC [52].** The table outlines the description of the parameters, abbreviation, mode of

545 measurement, pulse size, and the units of reporting.

Cell	Parameter	Measured	Pulse Size	Reported Units
WBC	White Blood Cell Count This is the number of leukocytes measured directly, multiplied by the calibration constant, and expressed as $n \times 10^3$ cells/ μ L	WBC bath	≥ 35 fL	$n \times 10^3$ cells/ μ L
RBC	Red Blood Cell Count This is the number of erythrocytes measured directly, multiplied by the calibration constant, and expressed as $n \times 10^6$ cells/ μ L	RBC bath	36 to 360 fL	$n \times 10^6$ cells/ μ L
Hb	Hemoglobin Concentration Weight (mass) of hemoglobin determined from the degree of absorbance found through photocurrent transmittance is: $Hb \text{ (g/dL)} = \text{Constant} \times \log_{10}(\text{Reference \% T} / \text{Sample \% T})$	WBC bath	525 nm	g/dL
Hct	Hematocrit This is the relative volume of packed erythrocytes to whole blood, computed as: $Hct \text{ (\%)} = RBC \times MCV / 10$	Computed	$RBC \times MCV / 10$	% Percent
MCV	Mean Cell Volume This is the average volume of individual erythrocytes derived from the RBC histogram.	Derived from RBC histogram	# x size of RBC / Total RBC	fL
MCH	Mean Cell Hemoglobin This is the weight of hemoglobin in the average erythrocyte count, computed as: $Hb / RBC \times 10$	Computed	$Hb / RBC \times 10$	pg
MCHC	Mean Cell Hemoglobin Concentration This is the average weight of hemoglobin in a measured dilution, computed as: $Hb / Hct \times 100$	Computed	$Hb / Hct \times 100$	g/dL
RDW	Red Cell Distribution Width RDW represents the size distribution spread of the erythrocyte population derived from the RBC histogram. It is the coefficient of variation (CV), expressed in percent, of the RBC size distribution.	Derived from RBC histogram	CV expressed in % of the RBC size distribution	% Percent
Plt	Platelet Count This is the number of thrombocytes derived from the Plt histogram and multiplied by a calibration constant. This number is expressed as: $n \times 10^3$ cells/ μ L	RBC bath	2 to 20 fL	$n \times 10^3$ cells/ μ L
MPV	Mean Platelet Volume MPV is the average volume of individual platelets derived from the Plt histogram. It represents the mean volume of the Plt population under the fitted	Derived from Plt histogram	Mean volume of Plt population under the fitted curve x constant	fL

	Plt curve multiplied by a calibration constant, and expressed in femtoliters.			
NE%	Neutrophil Percent The percentages of leukocytes from each category are derived from the scatterplot.	Derived from scatterplot	# cells inside NE area/# cells inside total cell area x 100	% Percent
NE #	Neutrophil Number The absolute numbers of leukocytes in each category are computed from the WBC count and the differential percentage parameters.	Absolute number	NE%/100 x WBC Count	10 ³ cells/ μ L
LY%	Lymphocyte Percent The percentages of leukocytes from each category are derived from the scatterplot.	Derived from scatterplot	# cells inside LY area/# cells inside total cell area x 100	% Percent
LY#	Lymphocyte Number The absolute numbers of leukocytes in each category are computed from the WBC count and the differential percentage parameters.	Absolute number	Ly%/100 x WBC Count	10 ³ cells/ μ L
MO%	Monocyte Percent The percentages of leukocytes from each category are derived from the scatterplot.	Derived from scatterplot	# cells inside MO area/# cells inside total cell area x 100	% Percent
MO#	Monocyte Number The absolute numbers of leukocytes in each category are computed from the WBC count and the differential percentage parameters.	Absolute number	MO%/100 x WBC Count	10 ³ cells/ μ L

546 *PDW - Platelet Distribution Width and Pct - Plateletcrit are NOT for diagnostic use and do not print. Coulter uses the value for

547 PDW is an internal check on the reported platelet parameters

548

549 **Supplementary Table 2** The odds ratio of median categories providing the odd of being diagnosed with
 550 either nMI, UM, and SM. The median categories were; low and high levels.

<i>Predict clinical diagnosis of UM</i>	<i>Estimate</i>	<i>S.E</i>	<i>OR</i>	<i>2.5%</i>	<i>97.5%</i>	<i>Pr(>Chi)</i>
(Intercept)	1.73	0.45	5.62	2.34	13.49	
WBC count - High Levels	-0.1	0.2	0.90	0.60	1.34	***
RBC count - High Levels	-0.1	0.17	0.91	0.65	1.27	***
Hb level - High Levels	-0.43	0.23	0.65	0.42	1.03	***
Hematocrit - High Levels	-0.71	0.22	0.49	0.32	0.76	***
Platelet count - High Levels	-2.26	0.14	0.10	0.08	0.14	***
Mean cell volume - High Levels	-0.21	0.2	0.81	0.55	1.20	
Lymphocytes count - High Levels	-0.77	0.19	0.46	0.32	0.67	***
Mixed cells % - High Levels	-0.26	0.17	0.77	0.55	1.08	***
Neutrophils % - High Levels	0.3	0.36	1.35	0.68	2.74	***
Mean cell hb conc - High Levels	0.23	0.16	1.26	0.93	1.71	**
Mean corp hb - High Levels	0.58	0.21	1.79	1.18	2.73	**
RBC Dist width % - High Levels	0.7	0.16	2.02	1.48	2.76	***
Mean platelet vl - High Levels	-0.32	0.15	0.72	0.54	0.96	**
Platelet distr width - High Levels	-0.4	0.14	0.67	0.50	0.88	**
Lymphocytes % - High Levels	-0.29	0.35	0.74	0.38	1.49	
Mixed cells count - High Levels	-0.23	0.19	0.80	0.55	1.16	
Neutrophils count - High Levels	0.34	0.2	1.40	0.94	2.09	.

<i>Predict clinical diagnosis of SM</i>	<i>Estimate</i>	<i>S.E</i>	<i>OR</i>	<i>2.5%</i>	<i>97.5%</i>	<i>Pr(>Chi)</i>
(Intercept)	3.87	1.03	47.79	6.75	390.36	
WBC count - High Levels	-0.46	0.59	0.63	0.20	2.00	***
RBC count - High Levels	-2.06	0.57	0.13	0.04	0.40	***
Hb level - High Levels	-2.25	0.69	0.11	0.03	0.40	***
Hematocrit - High Levels	-1.31	0.73	0.27	0.06	1.10	***
Platelet count - High Levels	-3.24	0.42	0.04	0.02	0.09	***
Mean cell volume - High Levels	-1.33	0.5	0.26	0.10	0.68	***
Lymphocytes count - High Levels	1.57	0.57	4.83	1.64	15.33	
Mixed cells % - High Levels	-0.42	0.45	0.66	0.27	1.59	**
Neutrophils % - High Levels	0.73	0.84	2.08	0.41	10.74	**
Mean cell hb conc - High Levels	3.97	0.54	52.89	19.25	161.79	***
Mean corp hb - High Levels	-0.69	0.55	0.50	0.17	1.46	.
RBC Dist width % - High Levels	1.55	0.43	4.72	2.07	11.10	***
Mean platelet vl - High Levels	-4.52	0.52	0.01	0.00	0.03	***
Platelet distr width - High Levels	3.27	0.47	26.33	10.89	70.04	***
Lymphocytes % - High Levels	-0.94	0.77	0.39	0.08	1.71	
Mixed cells count - High Levels	-0.17	0.55	0.84	0.28	2.49	
Neutrophils count - High Levels	0.38	0.54	1.46	0.51	4.20	

551 **OR-odds ratio, S.E – Standard Error, Pr (>Chi) –statistical estimate**

552 *Supplementary table 3 Performance evaluation of six machine learning models to classify clinical*
553 *malaria outcomes*


	ANN	UM vs nMI	SM vs nMI
Model type		Binary model	Binary model
Data splitting			
	Total data (100%)	n=1681	n=1504
	Training & validation data (80%)	n=1345	n=1204
	Testing data (20%)	n=336	n=300
	Training performance		
	Training accuracy	0.856	0.985
ANN	Testing performance		
	Testing accuracy	0.801	0.960
	Kappa	0.583	0.913
	Precision	0.780	0.971
	Recall	0.717	0.918
	F1- Score	0.747	0.944
Logistic Regression	Training performance		
	Training accuracy	0.817	0.962
	Testing performance		
	Testing accuracy	0.815	0.947
	Kappa	0.615	0.884
	Precision	0.803	0.934
	Recall	0.734	0.917
	F1- Score	0.767	0.925
Multivariate Adaptive Regression Splines	Training performance		
	Training accuracy	0.820	0.980
	Testing performance		
	Testing accuracy	0.786	0.973
	Kappa	0.542	0.942
	Precision	0.742	0.972
	Recall	0.685	0.954
F1- Score	0.712	0.963	
Decision Trees	Training performance		
	Training accuracy	0.794	0.937
	Testing performance		
	Testing accuracy	0.777	0.930
	Kappa	0.533	0.848
	Precision	0.704	0.899
	Recall	0.731	0.907
	F1- Score	0.717	0.903
Random Forest	Training performance		
	Training accuracy	0.817	0.982
	Testing performance		
	Testing accuracy	0.815	0.960
	Kappa	0.614	0.914
	Precision	0.808	0.936
	Recall	0.723	0.954
	F1- Score	0.765	0.945
SVM	Training performance		
	Training accuracy	0.822	0.981
	Testing performance		

	Testing accuracy	0.827	0.97
	Kappa	0.650	0.936
	Precision	0.849	0.955
	Recall	0.761	0.996
	F1- Score	0.803	0.959

554

555


561



562

563 **Supplementary figure 2 Artificial Neural Network Schematic.** Keras Model that is composed of a linear
564 stack of input layers, three hidden layers and one output layer. The input layer composed of an input shape
565 of 15 haematological parameters (RBC parameters, WBC parameters, and Platelet indices). The hidden
566 layers are each composed of a representative 16-stacked unit with ReLU as the activation function. The output
567 layer had sigmoid function as the activation function and uniform initialization. Interpretations of the model
568 classifications were made using local interpretable model-agnostic explanations (LIME Package in R) [41].

569



570

571 **Supplementary figure 3 Plot for the training and validation history of the ANN.** The figure indicates

572 training and validation history of the model, which shows how accuracy and loss are leveling off, as well

573 as the divergence between training and validation accuracy and training and validation loss. (A and B)

574 Multi-classification of (SM vs. UM vs. nMI) accuracy and loss respectively. (C and D) Accuracy and loss


575 respectively for ANN (UM vs. nMI) binary classifier. (E and F) Accuracy and loss respectively for the

576 ANN (SM vs. nMI) binary classifier. The plots show a minimal model gap between training and validation.

577

578

579



580

581 **Supplementary figure 4 Case by case analysis of the classification capability of the ML models.**

582 Samples of four cases in the test dataset were selected to indicate the predictions for each case. Case 1 and


583 4 are nMI patients, while case 2 and 3 are UM patients. The bars indicate the feature weights for each

584 haematological parameter and whether it is predictive of malaria (supports) or not (contradicts). This figure

585 highlights how the parameters can be used for precision medicine.

586

587



588


589 **Supplementary figure 5** Density estimates of the haematological parameters between nMI and UM cases

590 for sub-sampled data from Kintampo only.

591

592

593



594

595 **Supplementary figure 6** Density estimates of the haematological parameters between nMI, and UM

596 cases for sub-sampled data from Kintampo only, as well limit of children under 4 years of age.

597 **References**

- 598 1. WHO. World Malaria Report; World Health Organization. 2018;4:186.
599 <http://apps.who.int/iris/bitstream/10665/254912/1/WHO-HTM-GMP-2017.4-eng.pdf?ua=1>. Accessed 15 Oct 2017.
- 600 2. Watson OJ, Sumner KM, Janko M, Goel V, Winskill P, Slater HC, et al. False-negative malaria rapid diagnostic
601 test results and their impact on community-based malaria surveys in sub-Saharan Africa. *BMJ Glob Heal*.
602 2019;4:e001582.
- 603 3. Mouatcho JC, Dean Goldring JP. Malaria rapid diagnostic tests: Challenges and prospects. *J Med Microbiol*.
604 2013;62:1491–505. doi:10.1099/jmm.0.052506-0.
- 605 4. WHO. False-negative RDT results and *P. falciparum* histidine-rich protein 2/3 gene deletions. *World Heal Organ*.
606 2017. doi:10.1186/1475-2875-10-166.
- 607 5. Wanja EW, Kuya N, Moranga C, Hickman M, Johnson JD, Moseti C, et al. Field evaluation of diagnostic
608 performance of malaria rapid diagnostic tests in western Kenya. *Malar J*. 2016;15:456. doi:10.1186/s12936-016-
609 1508-y.
- 610 6. Agaba BB, Yeka A, Nsohya S, Arinaitwe E, Nankabirwa J, Opigo J, et al. Systematic review of the status of
611 *pfhrp2* and *pfhrp3* gene deletion, approaches and methods used for its estimation and reporting in *Plasmodium*
612 *falciparum* populations in Africa: Review of published studies 2010-2019. *Malaria Journal*. 2019;18:355.
613 doi:10.1186/s12936-019-2987-4.
- 614 7. Ranadive N, Kunene S, Darteh S, Ntshalintshali N, Nhlabathi N, Dlamini N, et al. Limitations of Rapid
615 Diagnostic Testing in Patients with Suspected Malaria: A Diagnostic Accuracy Evaluation from Swaziland, a Low-
616 Endemicity Country Aiming for Malaria Elimination. *Clin Infect Dis*. 2017;64:1221–7. doi:10.1093/cid/cix131.
- 617 8. Watson OJ, Sumner KM, Janko M, Goel V, Winskill P, Slater HC, et al. False-negative malaria rapid diagnostic
618 test results and their impact on community-based malaria surveys in sub-Saharan Africa. *BMJ Glob Heal*.
619 2019;4:e001582. doi:10.1136/bmjgh-2019-001582.
- 620 9. Agaba BB, Yeka A, Nsohya S, Arinaitwe E, Nankabirwa J, Opigo J, et al. Systematic review of the status of
621 *pfhrp2* and *pfhrp3* gene deletion, approaches and methods used for its estimation and reporting in *Plasmodium*

- 622 falciparum populations in Africa: review of published studies 2010–2019. *Malar J.* 2019;18:355.
623 doi:10.1186/s12936-019-2987-4.
- 624 10. Angelo KM, Libman M, Caumes E, Hamer DH, Kain KC, Leder K, et al. Malaria after international travel: a
625 GeoSentinel analysis, 2003-2016. *Malar J.* 2017;16:293. doi:10.1186/s12936-017-1936-3.
- 626 11. Grobusch MP, Schlagenhauf P. Self-Diagnosis and Self-Treatment of Malaria by the Traveler. *Travel Med.*
627 2019;:169–78. doi:10.1016/B978-0-323-54696-6.00016-1.
- 628 12. Lampah DA, Yeo TW, Malloy M, Kenangalem E, Douglas NM, Ronaldo D, et al. Severe malarial
629 thrombocytopenia: A risk factor for mortality in Papua, Indonesia. *J Infect Dis.* 2015;211:623–34.
- 630 13. Hanson J, Phu NH, Hasan MU, Charunwatthana P, Plewes K, Maude RJ, et al. The clinical implications of
631 thrombocytopenia in adults with severe falciparum malaria: A retrospective analysis. *BMC Med.* 2015;13:97.
632 doi:10.1186/s12916-015-0324-5.
- 633 14. White NJ. Anaemia and malaria. *Malar J.* 2018;17:371. doi:10.1186/s12936-018-2509-9.
- 634 15. Squire DS, Asmah RH, Brown CA, Adjei DN, Obeng-Nkrumah N, Ayeh-Kumi PF. Effect of Plasmodium
635 falciparum malaria parasites on haematological parameters in Ghanaian children. *J Parasit Dis.* 2016;40:303–11.
- 636 16. Muwonge H, Kikomeko S, Sembajjwe LF, Seguya A, Namugwanya C. How Reliable Are Haematological
637 Parameters in Predicting Uncomplicated Plasmodium falciparum Malaria in an Endemic Region? *ISRN Trop Med.*
638 2013;2013:1–9.
- 639 17. Anabire NG, Armah P, Francis A, Frank A, Osman A, Kanwugu N, et al. Evaluation of haematological indices
640 of childhood illnesses in Tamale Metropolis of Ghana. 2018; May:1–7.
- 641 18. Warimwe GM, Recker M, Kiragu EW, Buckee CO, Wambua J, Musyoki JN, et al. Plasmodium falciparum var
642 Gene Expression Homogeneity as a Marker of the Host-Parasite Relationship under Different Levels of Naturally
643 Acquired Immunity to Malaria. *PLoS One.* 2013;8:e70467. doi:10.1371/journal.pone.0070467.
- 644 19. Kotepui M, Phunphuech B, Phiwklam N, Chupeerach C, Duangmano S. Effect of malarial infection on
645 haematological parameters in population near Thailand-Myanmar border. *Malar J.* 2014;13.
- 646 20. Kotepui M, Piwklam D, PhunPhuech B, Phiwklam N, Chupeerach C, Duangmano S. Effects of malaria parasite

- 647 density on blood cell parameters. PLoS One. 2015;10.
- 648 21. Lee SJ, Stepniowska K, Anstey N, Ashley E, Barnes K, Binh TQ, et al. The relationship between the hemoglobin
649 concentration and the haematocrit in Plasmodium falciparum malaria. Malar J. 2008;7.
- 650 22. Lecun Y, Bengio Y, Hinton G. Deep learning. Nature. 2015;521:436–44.
- 651 23. Schmidhuber J. Deep Learning in Neural Networks: An Overview. 2014.
- 652 24. Mikolov T, Chen K, Corrado G, Dean J. Distributed Representations of Words and Phrases and Their
653 Compositionality. Proc Adv Neural Inf Process Syst. 2013;;1–9.
- 654 25. Mooney SJ, Pejaver V. Big Data in Public Health: Terminology, Machine Learning, and Privacy. Ssrn. 2018.
- 655 26. Camacho DM, Collins KM, Powers RK, Costello JC, Collins JJ. Next-Generation Machine Learning for
656 Biological Networks. Cell. 2018;173:1581–92. doi:10.1016/j.cell.2018.05.015.
- 657 27. Parveen R, Jalbani AH, Shaikh M, Memon KH, Siraj S, Nabi M, et al. Prediction of Malaria using Artificial
658 Neural Network. Int J Comput Sci Netw Secur. 2017;17:79–86.
- 659 28. Poostchi M, Silamut K, Maude RJ, Jaeger S, Thoma G. Image analysis and machine learning for detecting
660 malaria. Transl Res. 2018;194:36. doi:10.1016/J.TRSL.2017.12.004.
- 661 29. Bediako Y, Adams R, Reid AJ, Valletta JJ, Ndungu FM, Sodenkamp J, et al. Repeated clinical malaria episodes
662 are associated with modification of the immune system in children. BMC Med. 2019;17.
- 663 30. Kalantarmotamedi Y, Eastman RT, Guha R, Bender A. A systematic and prospectively validated approach for
664 identifying synergistic drug combinations against malaria. Malar J. 2018;17.
- 665 31. Shrinet J, Nandal UK, Adak T, Bhatnagar RK, Sunill S. Inference of the oxidative stress network in Anopheles
666 stephensi upon Plasmodium infection. PLoS One. 2014;9.
- 667 32. Thakur S, Dharavath R. Artificial neural network based prediction of malaria abundances using big data: A
668 knowledge capturing approach. Clin Epidemiol Glob Heal. 2019;7:121–6. doi:10.1016/J.CEGH.2018.03.001.
- 669 33. Butler KT, Davies DW, Cartwright H, Isayev O, Walsh A. Machine learning for molecular and materials
670 science. Nature. 2018;559:547–55. doi:10.1038/s41586-018-0337-2.

- 671 34. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. Towards Complete and
672 Accurate Reporting of Studies of Diagnostic Accuracy: The STARD Initiative. *Croatian Medical Journal*.
673 2003;44:635–8.
- 674 35. Cohen JF, Korevaar DA, Altman DG, Bruns DE, Gatsonis CA, Hooft L, et al. STARD 2015 guidelines for
675 reporting diagnostic accuracy studies: Explanation and elaboration. *BMJ Open*. 2016;6:e012799.
- 676 36. Oduro AR, Koram KA, Rogers W, Atuguba F, Ansah P, Anyorigiya T, et al. Severe falciparum malaria in young
677 children of the Kassena-Nankana district of northern Ghana. *Malar J*. 2007;6:96.
- 678 37. World Health Organization (WHO). Management of Severe Malaria: a practical handbook. 3rd edition. WHO
679 Library Cataloguing-in-Publication Data; 2013.
- 680 38. Iacobucci D, Posavac SS, Kardes FR, Schneider MJ, Popovich DL. The median split: Robust, refined, and
681 revived. *J Consum Psychol*. 2015;25:690–704.
- 682 39. Quintó L, Aponte JJ, Menéndez C, Sacarlal J, Aide P, Espasa M, et al. Relationship between hemoglobin and
683 haematocrit in the definition of anaemia. *Trop Med Int Heal*. 2006;11:1295–302.
- 684 40. Stephen Milborrow. Derived from mda:mars by Trevor Hastie and Rob Tibshirani. Uses Alan Miller’s Fortran
685 utilities with Thomas Lumley’s leaps wrapper. earth: Multivariate Adaptive Regression Splines version 5.1.2 from
686 CRAN. <https://rdr.io/cran/earth/>. Accessed 24 Aug 2020.
- 687 41. Ribeiro MT, Singh S, Guestrin C. “Why Should I Trust You?” Explaining the Predictions of Any Classifier.
688 *Scand J Infect Dis*. 2016;46:1135–44.
- 689 42. Liaw A, Wiener M. Classification and Regression by randomForest. 2002. <http://www.stat.berkeley.edu/>.
690 Accessed 12 May 2020.
- 691 43. Xu M, Papageorgiou DP, Abidi SZ, Dao M, Zhao H, Karniadakis GE. A deep convolutional neural network for
692 classification of red blood cells in sickle cell anemia. *PLOS Comput Biol*. 2017;13:e1005746.
693 doi:10.1371/journal.pcbi.1005746.
- 694 44. Gunčar G, Kukar M, Notar M, Brvar M, Černelč P, Notar M, et al. An application of machine learning to
695 haematological diagnosis. *Sci Rep*. 2018;8:411. doi:10.1038/s41598-017-18564-8.

- 696 45. White NJ, Pukrittayakamee S, Hien TT, Faiz MA, Mokuolu OA, Dondorp AM. Malaria. *Lancet* (London,
697 England). 2014;383:723–35. doi:10.1016/S0140-6736(13)60024-0.
- 698 46. Akinosoglou KS, Solomou EE, Gogos CA. Malaria: a haematological disease. *Hematology*. 2012;17:106–14.
699 doi:10.1179/102453312X13221316477336.
- 700 47. Cohen JM, Woolsey AM, Sabot OJ, Gething PW, Tatem AJ, Moonen B. Optimizing Investments in Malaria
701 Treatment and Diagnosis. *Science* (80-). 2012;338:612–4. doi:10.1126/science.1229045.
- 702 48. Kurup SP, Butler NS, Harty JT. T cell-mediated immunity to malaria. *Nat Rev Immunol*. 2019;19:457–71.
703 doi:10.1038/s41577-019-0158-z.
- 704 49. Ly A, Hansen DS. Development of B Cell Memory in Malaria. *Front Immunol*. 2019;10:559.
705 doi:10.3389/fimmu.2019.00559.
- 706 50. Mensah-Brown HE, Abugri J, Asante KP, Dwomoh D, Dosoo D, Atuguba F, et al. Assessing the impact of
707 differences in malaria transmission intensity on clinical and haematological indices in children with malaria. *Malar*
708 *J*. 2017;16:96. doi:10.1186/s12936-017-1745-8.
- 709 51. Godfellow I, Bengio Y, Courville A. *Deep Learning*. 2016.
- 710 52. CDC. *Clinical Reference Ranges*. 2013.
- 711
- 712